SAMRC Centre for Health Economics and Decision Science-PRICELESS SA, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Influenza Other Respir Viruses. 2022 Sep;16(5):873-880. doi: 10.1111/irv.12987. Epub 2022 Mar 30.
Influenza accounts for a substantial number of deaths and hospitalisations annually in South Africa. To address this disease burden, the South African National Department of Health introduced a trivalent inactivated influenza vaccination programme in 2010.
We adapted and populated the WHO Seasonal Influenza Immunization Costing Tool (WHO SIICT) with country-specific data to estimate the cost of the influenza vaccination programme in South Africa. Data were obtained through key-informant interviews at different levels of the health system and through a review of existing secondary data sources. Costs were estimated from a public provider perspective and expressed in 2018 prices. We conducted scenario analyses to assess the impact of different levels of programme expansion and the use of quadrivalent vaccines on total programme costs.
Total financial and economic costs were estimated at approximately USD 2.93 million and USD 7.91 million, respectively, while financial and economic cost per person immunised was estimated at USD 3.29 and USD 8.88, respectively. Expanding the programme by 5% and 10% increased economic cost per person immunised to USD 9.36 and USD 9.52 in the two scenarios, respectively. Finally, replacing trivalent inactivated influenza vaccine (TIV) with quadrivalent vaccine increased financial and economic costs to USD 4.89 and USD 10.48 per person immunised, respectively.
We adapted the WHO SIICT and provide estimates of the total costs of the seasonal influenza vaccination programme in South Africa. These estimates provide a basis for planning future programme expansion and may serve as inputs for cost-effectiveness analyses of seasonal influenza vaccination programmes.
在南非，流感每年导致大量死亡和住院。为了解决这一疾病负担，南非国家卫生部于 2010 年推出了三价灭活流感疫苗接种计划。
我们使用特定于国家的数据对世界卫生组织季节性流感免疫成本核算工具（WHO SIICT）进行了改编和填充，以估算南非流感疫苗接种计划的成本。数据通过在不同卫生系统层面的关键信息提供者访谈以及对现有二级数据源的审查获得。成本从公共提供者的角度进行估算，并以 2018 年的价格表示。我们进行了情景分析，以评估计划扩大不同程度和使用四价疫苗对总计划成本的影响。
总财务和经济成本分别估计约为 293 万美元和 7910 万美元，而每人免疫的财务和经济成本分别估计为 3.29 美元和 8.88 美元。在两个情景中，计划扩大 5%和 10%分别使每人免疫的经济成本增加到 9.36 美元和 9.52 美元。最后，用四价疫苗替代三价灭活流感疫苗（TIV）使每人免疫的财务和经济成本分别增加到 4.89 美元和 10.48 美元。
我们改编了世界卫生组织季节性流感免疫成本核算工具，并提供了南非季节性流感疫苗接种计划总成本的估计值。这些估计值为未来计划扩大提供了基础，并可能为季节性流感疫苗接种计划的成本效益分析提供输入。
